Science
Gustavo Viani
Gustavo Viani/sbradioterapia.com.br

Gustavo Viani: Immunotherapy + cCRT in Stage III NSCLC

Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared an article by Fabian Acker, et al. on X:

“Immunotherapy + cCRT in Stage III NSCLC: Breakthrough or Too Risky? 

Objective:

  • Assess efficacy & safety of immune checkpoint inhibitors (CPI) + concurrent chemoradiotherapy (cCRT).

Methods:

  • 7 trials, 653 patients •Endpoints: Pneumonitis, ORR, PFS, OS.

Results:

  • ORR: 69%.
  • Median PFS: 16.3 months.
  • Median OS: 39.5 months. 
  • 3-year OS: 53.1%.

Toxicity:

  • Pneumonitis (any grade): 33%.
  • Grade 3–5 pneumonitis: 7%.
  • Dual CPI (PD-1 + CTLA4) → 16% mortality.

Takeaways:

  • Single-agent CPI + cCRT is feasible.
  • Dual CPI = high toxicity.
  • More trials needed (CheckMate-73L, EA5181, APOLO).

Gustavo Viani: Immunotherapy + cCRT in Stage III NSCLC

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis.

Authors: Fabian Acker, et al.

Gustavo Viani: Immunotherapy + cCRT in Stage III NSCLC

 

cancer Fabian Acker fight against cancer Global fight against cancer Gustavo Gustavo Viani immunotherapy non small cell lung cancer NSCLC OncoDaily Oncology pneumonitis RadOnc Ribeirão Preto Medical School